Latest & greatest articles for infliximab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infliximab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infliximab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infliximab

1. Infliximab

Infliximab Top results for infliximab - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for infliximab The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Renflexis - Infliximab

Renflexis - Infliximab Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated to include post

Health Canada - Drug and Health Product Register2018

3. Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis

Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis

European Medicines Agency - EPARs2018

4. Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis

Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis European Journal of Rheumatology ISSN 2147-9720 | E-ISSN 2148-4279 Volume: 5 Issue: 1 Mar 2018 Case Report Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis 1 , 2 , 2 , 2 , 3 , 2 , 2 1 Department of Internal Medicine, Hacettepe University School (...) of Medicine, Ankara, Turkey 2 Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey 3 Department of Medical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey Eur J Rheumatol 2018; 5: 75-78 DOI: 10.5152/eurjrheum.2016.15081 Key Words: Still’s disease, pulmonary aspergillosis, tumor necrosis factor-alpha inhibitors, infliximab Abstract The use of anti-tumor necrosis factor alpha (anti-TNF-α) agents has increased during the past

European journal of rheumatology2018 Full Text: Link to full Text with Trip Pro

5. Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy

Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset password (...) If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × December 2017. Volume 13. Number 4 Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email Confirm email I accept the journal’s privacy

Evidencias en Pediatría2018

6. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction

Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction Gut Microbiota Offers Universal Biomarkers across Ethnicity in In?ammatory Bowel Disease Diagnosis and In?iximab Response Prediction Youlian Zhou, a,c Zhenjiang Zech Xu, d,k,l Yan He, b,j Yunsheng Yang, e Le Liu, a Qianyun Lin, a Yuqiang Nie, c Mingsong Li, a Fachao Zhi, a Side Liu, a Amnon Amir, d Antonio González, d Anupriya Tripathi, d Minhu Chen, f Gary D

mSystems2018 Full Text: Link to full Text with Trip Pro

7. infliximab (TBC)

infliximab (TBC) infliximab | CADTH.ca Find the information you need infliximab Generic Name: infliximab Brand Name: TBC Manufacturer: Merck Canada Inc. Indications: rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis Submission Type: New Project Status: Pending Call For Patient Input: August 4, 2017 Patient Input Closed

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2018

8. Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet’s disease after switching from infliximab originator

Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet’s disease after switching from infliximab originator 29308287 2018 11 13 2147-9720 4 4 2017 Dec European journal of rheumatology Eur J Rheumatol Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet's disease after switching from infliximab originator. 288-290 10.5152/eurjrheum.2017.16112 Three patients affected by Behçet's disease (BD) with severe uveitis and neurological involvement (...) in stable clinical remission and who rapidly relapsed after switching from reference infliximab (re-IFX) to biosimilar infliximab (bio-IFX) are reported. In order to observe the rules of local health authorities, two males and one female (38, 26, and 40 years old, respectively) with BD complicated by severe uveitis and neuro-Behçet and who were in prolonged remission, were switched from re-IFX to bio-IFX, with the same dosing regimen of 5 mg/kg intravenous infusions every 8 weeks. All three patients

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

9. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. BACKGROUND: TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim of NOR-SWITCH was to examine switching from originator infliximab to the less (...) expensive biosimilar CT-P13 regarding efficacy, safety, and immunogenicity. METHODS: The study is a randomised, non-inferiority, double-blind, phase 4 trial with 52 weeks of follow-up. Adult patients on stable treatment with infliximab originator treated in a hospital setting for at least 6 months were eligible for participation. Patients with informed consent were randomised in a 1:1 ratio to either continued infliximab originator or to switch to CT-P13 treatment, with unchanged dosing regimen. Data

Lancet2017

10. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product 28331376 2018 11 13 1179-156X 9 2017 Open access rheumatology : research and reviews Open Access Rheumatol Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. 29-35 10.2147/OARRR.S124975 To evaluate the efficacy and safety of the biosimilar infliximab in adult patients with inflammatory (...) arthritis switched from reference product in our center. In April 2014, patients attending our rheumatology service for infliximab infusions were switched from reference product to the biosimilar infliximab following consent and hospital approval. Around 34 patients with inflammatory arthritis were switched from reference product to biosimilar infliximab in 2014: 50% female, mean age 55 years (standard deviation=12.9), mean disease duration 14.79 years (9.7), median duration on infliximab 57 months

Open access rheumatology : research and reviews2017 Full Text: Link to full Text with Trip Pro

12. Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Switching from Innovator to Biosimilar (...) (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Published on: January 18, 2017 Project Number: RC0836-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with rheumatoid arthritis? What is the clinical effectiveness and safety of switching from innovator infliximab

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

15. Infliximab-Induced Lupus: A Case Report

Infliximab-Induced Lupus: A Case Report 29255743 2018 11 13 2341-4545 24 2 2017 Mar GE Portuguese journal of gastroenterology GE Port J Gastroenterol Infliximab-Induced Lupus: A Case Report. 84-88 10.1159/000450877 We report the case of a 48-year-old, leukodermic female diagnosed with ulcerative proctitis for 4 years and latent tuberculosis. She was allergic to salicylates and had a minor allergic reaction to infliximab (rash, vertigo, and headache). Thereafter, she started azathioprine (2.5 mg (...) /kg/day). She maintained intravenous infliximab, together with prophylaxis with clemastine and hydrocortisone, due to the steroid-dependent proctitis. The therapy was continued every 8 weeks with anti-tumor necrosis factor for about 3 years. The analytical evaluation when she was diagnosed with ulcerative proctitis (February 2011) showed negative antinuclear antibodies (ANA), double-stranded-DNA antibodies (anti-dsDNA), antineutrophil cytoplasmic antibodies and anti- Saccharomyces cerevisiae

GE Portuguese journal of gastroenterology2016 Full Text: Link to full Text with Trip Pro

16. Infliximab (Remicade Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease

Infliximab (Remicade Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease Infliximab (Remicade; Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease Infliximab (Remicade; Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) .. Infliximab (Remicade; Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Infliximab (IFX) (Remicade; Janssen Biotech Inc.) is a recombinant chimeric human-murine immunoglobulin G1 monoclonal antibody designed to target and block tumor necrosis factor-alpha (TNF-?) and, thereby, reduce inflammation and associated sequelae. For pediatric Crohn disease (CD), IFX

Health Technology Assessment (HTA) Database.2016

17. Comparison Of iNfliximab and ciclosporin in Steroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT)

Comparison Of iNfliximab and ciclosporin in Steroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT) Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found

NIHR HTA programme2016

18. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try

NIHR HTA programme2016

19. Flixabi (infliximab) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis

Flixabi (infliximab) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis

European Medicines Agency - EPARs2016

20. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display

NIHR HTA programme2016